ArticleDermatology reports2026
Clinical features, safety, and efficacy of combining Q-switched Nd:YAG laser and FOB
Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma is a benign skin condition characterized by hyperpigmented patches, primarily affecting the face, and significantly reducing patients' quality of life. Treatment is challenging due to its recurrent nature, with no single modality proving universally effective. The combination of Q-switched Nd:YAG laser treatment and FOB® Tri-White Serum (Hong Nhung Cosmetics Co., Ltd., Can Tho, Vietnam) may represent a promising new therapeutic approach. This cross-sectional descriptive study involved 85 female patients with melasma treated at two dermatological centers between July 2023 and June 2024. Patients underwent four Q-switched Nd:YAG laser sessions (1064 nm, 1.5-1.7 J/cm2) at 3-week intervals and applied FOB® Tri-White Serum twice or three times daily. Treatment effectiveness was assessed using the Melasma Area and Severity Index (MASI) score and the Felix Von Luschan skin color chart. Data were analyzed using Stata 17.0 MP, with p<0.05 considered statistically significant. The mean MASI score improved significantly from 7.5±4.7 to 4.9±3.5 (p<0.05), with a 69.4% response rate. Younger patients (<45 years), individuals with a shorter disease duration (≤36 months), and cases of mild-to-moderate melasma exhibited more favorable outcomes. Adverse effects from both the laser and serum were mild and transient. The combination of Q-switched Nd:YAG laser and FOB® Tri-White Serum is a safe and effective treatment for melasma, demonstrating significant improvement in pigmentation with minimal side effects. Further research is needed to validate these findings with larger sample sizes and control groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.